STOCK TITAN

INmune Bio Inc - INMB STOCK NEWS

Welcome to our dedicated news page for INmune Bio (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on INmune Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INmune Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INmune Bio's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.25%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.73%
Tags
none
INmune Bio Inc

Nasdaq:INMB

INMB Rankings

INMB Stock Data

209.59M
11.73M
34.92%
13.84%
7.75%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boca Raton

About INMB

inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.